CompletedNCT06041646
Repeated Igalmi and agitation in schizophrenia or bipolarity
About this title
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Read the official source — NCT06041646Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 2, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 29
- Sponsor
- BioXcel Therapeutics Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06041646
- Official title
Show the full official title
Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Rogers
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioXcel Therapeutics Inc.
Did this study involve medication?
Yes. The study involved medication, including Sublingual film containing Igalmi.
Who was this study for?
Listed age limits: 18 years to 65 years.
